Pediatric Blood & Cancer · 2023 · 16 citations · 10 references
MedicineOrthopedic SurgeryPediatricsOrthopedicsPediatric OncologyPediatric OrthopaedicsBone DisordersBone HealthPediatric SafetySlipped Capital Femoral EpiphysisAcute Slipped Capital Femoral EpiphysisBilateral Slipped Capital Femoral EpiphysisChronic Slipped Capital Femoral EpiphysisGrowth VelocityPediatric Bone DiseaseSlipped Capital Femoral Epiphysis CareSlipped Capital Femoral Epiphysis EvaluationTherapeutic Tyrosine Kinase Inhibitors
Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors (TKIs) are increasingly being used off label in pediatrics. Long-term safety data are limited, and serious toxicities unique to pediatrics may emerge. In a retrospective analysis of patients less than 18 years of age with recurrent/refractory FGFR altered gliomas treated with FGFR TKIs at MSKCC (n = 7), we observed slipped capital femoral epiphyses in three of seven patients along with increased linear growth velocity. Clinicians should closely monitor bone health and have a low index of suspicion for serious orthopedic complications including slipped capital femoral epiphyses and inform patients of related risks as part of consent when treating with FGFR TKIs.
10
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Yohann Loriot, Andrea Necchi, Se Hoon Park et al. · New England Journal of Medicine · 2019 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +15
Fibroblast Growth Factor Receptor 3 Is a Negative Regulator of Bone Growth
Anthony Wynshaw‐Boris, Fen Zhou, Ann Kuo et al. · Cell · 1996 · 1.1K citations · Full text
Randall T. Loder, Mary Lou V. H. Greenfield · Journal of Pediatric Orthopaedics · 2001 · 49 citations